



## Evaluation of *in-vitro* anticancer activity assessment on breast cancer cell line MCF-7

Binay Kumar Mahto<sup>1\*</sup>, Rajendra Bapna<sup>1</sup>, Ajay Kumar Shukla<sup>2</sup>

<sup>1</sup>. Department of Pharmaceutical Sciences, Dr. A.P.J Abdul Kalam University, Indore, India.

<sup>2</sup>. Institute of Pharmacy, Dr. Ram Manohar Lohia Avadh University, Ayodhya, India

Corresponding author email id: [ashukla1007@gmail.com](mailto:ashukla1007@gmail.com)

### ABSTRACT

The aim of research work to investigate the *in-vitro* anticancer activity on breast cancer cell line MCF-7 using poly-herbal hydroalcoholic extract of *Ocimum sanctum*, *Curcuma longa*, *Emblca officinalis*, *Terimialia bellerica*, *Terimialia chebula*, *Piper longum*, *Piper nigrum* and *Zingiber officinale*. The poly-herbal hydro-alcoholic extract prepared were using coarsely powder of *Ocimum sanctum* 50mg, *Curcuma longa* 50mg, *Emblca officinalis* 50mg, *Terimialia bellerica* 50mg, *Terimialia chebula* 50mg, *Piper longum* 50mg, *Piper nigrum* 25mg, and *Zingiber officinale* 25mg. The poly-herbal hydroalcoholic extract was used for development of poly-herbal capsule for the treatment and management of cancer disease. The developed poly-herbal combination showed significant anticancer activity against MCF-7 breast cancer cell line. The poly-herbal hydroalcoholic extract was found to be IC<sub>50</sub> 35.44 µg/ml effective against MCF-7 breast cancer cell line. Thus, the poly-herbal hydroalcoholic extract showed the therapeutic potential against cancer cells which can be exploited in further investigation against carcinogenesis. These potential bioactive compounds having combination might be effective for the treatment and management of breast cancer.

**Keywords:** Breast cancer, poly-herbal formulation, MCF-7 breast cancer cell line.

Received 19.03.2023

Revised 14.04.2023

Accepted 21.05.2023

### INTRODUCTION

Medicinal drugs are most important for all humans. These herbal drugs are used for treatment and management of diseases by peoples from ancient times. As per the world health organization (WHO), breast cancer disease is a increasing health issue worldwide and is the second most cause of death. Average 1 in 10 women is diagnosed with breast cancer at some stage of life. World Health Organization (WHO), approved that "natural plants are having more bioactive molecules that have been reported their therapeutic benefits, or which are mother sources of chemo-pharmaceutical semi-synthesis [1-2].

According to various researchers reports estimated that even modern time approximately 65-75% of the World's populations depend on medicinal plants for treatment and management of diseases [3-4].

Breast cancers diseases have been reported worldwide in woman. Breast cancer creates significant morbidity and mortality amongst women [5]. Lack of effective therapeutic drugs for control and treatment of breast cancers, and the huge financial burden placed on individuals and nations mean urgent action must be taken in the fight and treatment and management of breast cancer disease. The sides' effects produce by conventional chemotherapy for long time treatment. These side effects can be removed by using herbal bioactive medicines at economic level. In the recent years, peoples interest highly increases towards natural products for safe cancer prevention, current approaches have been focused on the use of food and ethno medicinal plants as sources of natural products that could used for effectively control cancer diseases [6-8].

In poly-herbal formulation is a excellent concept and suitable and right for the treatment and management of chronic diseases such as cancer diseases. Bioactive compounds have been used by Ayurveda doctors to treat and manage the condition of breast cancer. The beneficial compounds flavonoids, saponins, tannins, gums, and mucilage are all secondary metabolites of natural plants [9-10]. Natural remedies are incredibly efficient, safe, and economical for treating numerous diseases [11]. The anticancer activity of a poly-herbal combination extract (PHCE) containing leaf extracts of *Ocimum sanctum*, *Curcuma longa*, *Emblca officinalis*, *Terimialia bellerica*, *Terimialia chebula*, *Piper longum*, *Piper nigrum*, and *Zingiber officinale* was selected [12] Selected poly-herbal combinations have never been employed before by any researcher, and there are currently no research publications available. These are

all medicinal herbs potential anticancer bioactive molecules. As a result, these PHCE were chosen for the treatment and management of breast cancer disease. Many researchers have been reported and found good results but need to more research work for development of potential natural products. Our objective of present research work was the development of poly-herbal combination for the treatment and management of breast cancer disease [13-17]. Name of plants and their potential bioactive molecules pharmacological properties are shown in below Table 1.

**Table 1 Name of plants and their potential bioactive molecules pharmacological properties**

Name of plants	Phytochemicals	Pharmacological properties
<i>Ocimum sanctum</i> [18].	Carvacrol, methyl carvicol, urosolic acid, limatrol, Caryophyllene, sitosterol; xylose and polysaccharides	Anticancer, anti-diabetic, antifungal, antimicrobial, cardioprotective etc.
<i>Curcuma longa</i> [19-20].	Curcuminoids, turmerone (40%) and curone demethoxycurcumin, bisdemethoxycurcumin and many more.	Treatment for anti-inflammatory, antiallergic, antimicrobial, anticancer, hepatoprotective, neuroprotective etc.
<i>Emblica officinalis</i> [21].	Ellagic acid, tannins, gallic acid, minerals, vitamins, amino acids, fixed oils, and flavonoids such as rutin and quercetin are all polyphenols.	Digestive problems, cancer, osteoporosis, hypertension, neurological problems etc.
Mixture of Haritaki, Bibhitaki and Amalaki [22-23].	Flavonoids, alkaloids, phenols	Hepatoprotective, ulcerative colitis, cardiovascular illness, low liver function, large intestine inflammation
Trikatu (Mixture of black pepper, ginger and long pepper [24-25].	Piperine, gingerols, shogaols, and paradols, oleoresins, and alkaloids are some of the compounds found in ginger.	Fever, gastrointestinal and GI issues, urinary difficulties, hepatoprotective, neuralgia, and boils, to name a few.

## MATERIALS AND METHODS

### Collection of plants and analytical reagents

Selected plants materials were collected from local market like as *Ocimum sanctum*, *Curcuma longa*, *Emblica officinalis*, *Terimimalia bellerica*, *Terimimalia chebula*, *Piper longum*, *Piper nigrum* and *Zingiber officinale*. The plants materials are verified by the Central Ayurvedic Research Institute, Jhansi, Uttar Pradesh with accession number CARI/H/13212021, CARI/H/13222021, CARI/H/13232021, CARI/H/13242021, CARI/H/13252021, CARI/H/13262021, CARI/H/13272021, CARI/H/13282021, CARI/H/132292021, by Pharmacognosist, Dr. Sandeep Kumar Singh. All the required chemicals and reagents are analytical grade were used. The cancer cell lines were obtained from the National Center for Cell Sciences Pune, India.

**Table 1: Herbal Drugs Used in Poly-herbal powder Formulation**

Name of the plant	Common Name	Parts Used
<i>Ocimum sanctum</i>	Tulsi	Leaves
<i>Curcuma longa</i>	Turmeric	Rhizomes
<i>Emblica officinalis</i>	Amla	Fruits
<i>Terimimalia bellerica</i>	Baheda	Fruits
<i>Terimimalia chebula</i>	Harde	Fruits
<i>Piper longum</i>	Long pepper	Fruit
<i>Piper nigrum</i>	Kali mirch	Fruit
<i>Zingiber officinale</i>	Ginger powder	Rhizome

### Formula for Poly-herbal formulation

The poly-herbal hydro-alcoholic extract prepared were using coarsely powder of *Ocimum sanctum* 50mg, *Curcuma longa* 50mg, *Emblica officinalis* 50mg, *Terimimalia bellerica* 50mg, *Terimimalia chebula* 50mg, *Piper longum* 50mg, *Piper nigrum* 25mg, and *Zingiber officinale* 25mg [18-20].

### Extraction

The prepared poly-herbal combination of coarsely powder was used and extracted with using distilled water 30%: ethanol 70% ratio with maceration method. The powder poly-herbal combination was

dipped into the solvent ration (30:70) for 15 days and after completion of extraction, filtered and concentrated with the help of rotator evaporator method. The hydroalcoholic extract stored in airtight container and stored for further used [21-28].

**Maintenance of cell lines:**

The MCF-7 breast cancer cell line was obtained from NCCS, Pune, India. The cells were maintained in DMEM high glucose media supplemented with 10 % FBS along with the 1% antibiotic-antimycotic solution in the atmosphere of 5% CO<sub>2</sub>, 18-20% O<sub>2</sub> at 37°C temperature in the CO<sub>2</sub> incubator and sub-cultured for every 2days.

**Background of the study:**

3-(4,5-Dimethylthiazol-2-Yl)-2,5-Diphenyltetrazolium Bromide (MTT) assay is a colorimetric assay used for the determination of cell proliferation and cytotoxicity, based on reduction of the yellow colored water soluble tetrazolium dye MTT to formazan crystals. Mitochondrial lactate dehydrogenase produced by live cells reduces MTT to insoluble formazan crystals, which upon dissolution into an appropriate solvent exhibits purple color, the intensity of which is proportional to the number of viable cells and can be measured spectrophotometrically at 570nm [29-31].

**In-vitro anticancer activity assessment (MTT assay)**

The prepared poly-herbal hydroalcoholic extracts were tested for anticancer activity assessment using MTT- assay MCF-7 breast cancer cell line. In-vitro anticancer activity assessment under seed 200µl cell suspension is in a 96-well plate at required cell density (20,000 cells per well), without the test agent. Allow the cells to grow for about 24 hours. Add appropriate concentrations of the test agent (Mentioned in the results - Excel sheet). Incubate the plate for 24hrs at 37°C in a 5% CO<sub>2</sub> atmosphere. After the incubation period, takeout the plates from incubator, and remove spent media and add MTT reagent to a final concentration of 0.5mg/mL of total volume. Wrap the plate with aluminium foil to avoid exposure to light. Return the plates to the incubator and incubate for 3 hours. (Note: Incubation time varies for different cell lines. Within one experiment, incubation time should be kept constant while making comparisons.) Remove the MTT reagent and then add 100µl of solubilisation solution (DMSO). Gentle stirring in a gyratory shaker will enhance dissolution. Occasionally, pipetting up and down may be required to completely dissolve the MTT formazan crystals especially in dense cultures. Read the absorbance on a spectrophotometer or an ELISA reader at 570nm wavelength [Sangeeta et al., 2012, Kaur et al., 2018]. The IC<sub>50</sub> value was determined by using linear regression equation i.e.

$$Y = Mx + C.$$

Here, Y = 50, M and C values were derived from the viability graph.

% Cell viability is calculated using the below formula:

$$\% \text{ Cell viability} = [\text{Abs of treated cells} / \text{Abs of Untreated cells}] * 100$$


**RESULTS**

The developed poly-herbal powder formulation of anticancer activity assessment test was performed by using in-vitro method. The Observations in Statistical data of MTT cytotoxicity Study suggesting us that against MCF-7 breast cancer cell line, Test Compounds namely S1 showing significant cytotoxic potential properties with the IC<sub>50</sub> concentrations at 35.44µG/ml used in the study. The compound, S1 showing effective cytotoxicity on MCF-7 breast cancer cell line and may be considered as potent anti-breast cancer agent due to their low IC<sub>50</sub> values on MCF-7 breast cancer cell line. Overall, S1 compound showing effective anti-cancer potency on Human breast cancer cells. Further studies like Cell Cycle Study by PI staining, Apoptosis study by Annexin V/PI staining, Apoptotic Protein expressions like Caspase 3,7,9, Bcl2,p53 and ROS study to evaluate the mechanism of action of test compounds viz., S1 behind the anticancer potential in invitro conditions. The results of in-vitro cancer cell line study shown in Table 2 and Fig.1 respectively.

**In-vitro anticancer activity assessment**

**Table 2: Table showing the IC<sub>50</sub> concentrations of the Test compounds, S1 against MCF-7 breast cancer cell lines after the incubation period of 24hrs.**

S. NO	Sample code	IC <sub>50</sub> (µG/ml)
		MCF-7 Cell
1	F1	35.44



**Fig. 1. Bar graph showing the % cell viability of Test compounds against MCF-7 breast cancer cell line by MTT study.**

## DISCUSSION

Various types of herbal medicines have been used as curative agents in different parts of the world. Drugs derived from traditional herbs may have possible therapeutic significance in the treatment of cancer diseases. In the present research work poly-herbal powder mixtures of selected plants were screened for their anti-cancer activity. Poly-herbal mixture of plant shows significant anti-cancer activity on MCF-7 breast cancer cell line. Further studies using more specific methods are required to explore the constituents responsible for the activity and the mechanism of this activity which might prove important and improved therapies for the treatment and management of breast cancer diseases [32-38].

## ACKNOWLEDGEMENT

The authors are thankful to Dr. A.P.J Abdul Kalam University (Department of Pharmaceutical Sciences, India for providing the research facilities for conducting smooth research work.

## REFERENCES

- Huai, H. (2010). Ethnomedicinal analysis of toxic plants from five ethnic groups in china. *Ethnobotany Research and Applications*; 169-79.
- Husain, S.Z., Malik, R.N., Javaid, M., Bibi, S. (2008). Ethnobotanical properties and uses of medicinal plants of morghah biodiversity park rawalpindi. *Pakistan Journal of Botany*. 1897-911.
- Gupta, A.K., Tandon, N. (2004). Review of Indian Medicinal Plants. *Indian Council of Medical Research* New Delhi, India; 10.
- Sharma, S.K. (1998). Medicinal plants used in ayurveda, National Academy of Ayurveda. *Ministry of Health & Family Welfare*, Government of India; 12.
- Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., Smigal, C. et al (2006). Cancer Statistics. *CA Cancer J Clin*; 106-13.
- Ferguson, P.J., Kurowska, E., Freeman, D.J., Chambers, A.F., Koropatnick, D.J. (2004). A flavonoid fraction from cranberry extract inhibits proliferation of human tumor cell lines. *J Nutr*; 1529-1535.
- Jo, E.H., Hong, H.D., Ahn, N.C., Jung, J.W., Yang, S.R., Park, J.S. et al (2004). Modulations of the bcl-2/bax family were involved in the chemopreventive effects of licorice root (*Glycyrrhiza uralensis* Fisch) in MCF-7 Human Breast Cancer Cell. *J Agric Food Chem*; 1715-171.
- Mukherjee, A.K., Basu, S., Sarkar, N., Ghosh, A.C. (2001). Advances in cancer therapy with plant based natural products. *Curr Med Chem*; 1467-1486.
- Charde, M., Shukla, A., Bukhariya, V., Mehta, J., Chakole, R. (2011). Herbal remedies as antioxidants: an overview. *International Journal of Pharmacological Research*; 1(2):1-10.
- Garg, S., Garg, A., Shukla, A., Dev, S.K., Bishnoi, R.S., Kumar, M. (2018). Review on antioxidant evaluation methods: in-vitro and in-vivo models. *Asian Journal of Pharmacy and Pharmacology*; 4(2): 147-154.
- Madhava, C.K., Sivaji, K., Tulsi, R.K. (2008). Flowering plants of chithor district. 1st edition. India: Andhrapradesh, *Students Offset Printers*; 301-305.
- DiJoseph, J.H., Eash, J.R., Mir, G.N. (1987). Gastric anti-secretory and antiulcer effects of WHR1582A, A compound exerting alpha-2 adrenoceptor agonist activity. *J Pharmacol Exp Ther*; 241(1): 97-102.

13. Asif, M. (2012). A review on phytochemical and ethno pharmacological activities of *Curculigo orchoides*. *Mahidol University Journal of Pharmaceutical Sciences*; 1-10.
14. Labban, L. (2014). Medicinal and pharmacological properties of turmeric (*Curcuma longa*): a review. *Int J Pharm Biomed Sci*; 17-23.
15. Pandey, P., Garg, A., Shukla, A. (2016). Preliminary Phytochemical and physicochemical investigation and thin layer chromatography of *Butea monosperma* flower extract. *Journal of Medical Pharmaceutical and Allied Sciences*; 1-10.
16. Ghatge, N.B., Hazra, B., Sarkar, R., Mandal, N. (2014). In-vitro anticancer activity of *Spondias pinnata* bark on human lung and breast carcinoma. *Cytotechnology*; 209-218.
17. Balabhaskar, R., Vijayalakshmi, K. (2019). Evaluation of anticancer activity of ethanol extract of *Bauhinia tomentosa* Linn. on A549, Human Lung Carcinoma Cell lines. *Research J. Pharm. and Tech*; 2748-275).
18. Pattanayak, P., Behera, P., Das, D., Panda, S.K. *Ocimum sanctum* Linn. (2010). A reservoir plant for therapeutic applications: An overview. *Pharmacognosy Reviews*; 4(7):95-105.
19. Fuloria, S., Mehta, J., Chandel, A., Sekar, M., Rani, N.N.I.M., Begum, M.Y., Subramaniyan, V., Chidambaram, K., Thangavelu, L., Nordin, R., Wu, Y.S., Sathasivam, K.V., Lum, P.T., Meenakshi, D.U., Kumarasamy, V., Azad, A.K and Fuloria, N.K. (2022). A comprehensive review on the therapeutic potential of *curcuma longa* linn. in relation to its major active constituent Curcumin. *Front. Pharmacol*; 1-27.
20. Reddy, A.V., Suresh, J., Yadav, H.K.S., Singh, A. (2012). A review on *Curcuma longa*. *Research J. Pharm. and Tech*; 5(2):158-165.
21. Variya Bhavesh, C., Bakrania, A.K., Patel, S.S. (2016). *Embliba officinalis* (Amla): A review for its phytochemistry, ethnomedicinal uses and medicinal potentials with respect to molecular mechanisms. *Pharmacological Research*; 1-75.
22. Parveen, R., Shamsi, T.N., Singh, G., Athar, T., Fatima, S. (2018). Phytochemical analysis and in-vitro biochemical characterization of aqueous and methanolic extract of *triphalala*, A Conventional Herbal Remedy. *Biotechnology Reports*; 17:126-136.
23. Wei, X., Luo, C., He, Y., Huang, H., Ran, F., Liao, W., Tan, P., Fan, S., Cheng, Y., Zhang, D., Lin, J., Han, L. (2021). Hepatoprotective Effects of Different Extracts from *Triphala* against CCl<sub>4</sub>-Induced Acute Liver Injury in Mice. *Front. Pharmacol*; 12:1-18.
24. Johri, R.K., Zutshi, U. (1997). An ayurvedic formulation 'trikatu' and its constituents. *Journal of Ethnopharmacology*; 37(2):85-91.
25. Kumar, S.V.S., Mishra, S.H. (2004). Hepatoprotective activity of the *trikatu churna*-an ayurvedic formulation. *Indian Journal of Pharmaceutical Sciences*; 365-367.
26. Mahto, B.K., Patel, R., Bapna, R., Shukla, A.K. (2022). Development and standardization of a poly herbal formulation. *The Scientific Temper*; 13(2):118-125.
27. Mehta, S., Garg, A., Garg, S., Kumar, M., Shukla, A. (2018). Concise report on standardization of herbal drugs and its products. *Advance Pharmaceutical Journal*. 3(3):83-89.
28. Sharma, P., Pandey, P., Gupta, R., Roshan, S., Jain, A. P., Shukla, A., Shukla, R., Garg, A., Pasi, A. (2013). Development of quality control parameters for henna powder. *Int. J. Pharm. Sci. Rev. Res*; 21(1):293-295.
29. Karpagam, T., Jannathul, Firdous, Revathy., Shanmuga, Priya., Varalakshmi, B., Gomathi, S., Geetha, S., Noorzaid, Muhamad. (2019). Anti-cancer activity of aloe vera ethanolic leaves extract against in-vitro cancer cells. *Research J. Pharm. and Tech*; 2167-217.
30. Mai, M., Al-Oqail. (2021). Anticancer efficacies of *Krameria lappacea* extracts against human breast cancer cell line (MCF-7): role of oxidative stress and ROS generation. *Saudi Pharmaceutical Journal*; 244-251.
31. Sangeeta, S., Tanavade, S.M.T., Nilofer, Naikwade., Dhanyakumar, D.C. (2012). In-vitro anticancer activity of ethanolic and aqueous extracts of *Peristrophe bivalvis merrill*. *Research J. Pharm. and Tech*; 1324-1327.
32. Bajaj, J., Dave, V., Sharma, S., Shukla, A., Chakole, R.D. (2012). Pharmacognostical and phytochemical studies on *Achyranthes aspera*. *World Journal of Pharmacy and Pharmaceutical Sciences*; 1(4):1316-1331.
33. Gupta, M, Lodhi, S, Shukla, A. (2015). Preliminary phytochemical analysis and in-vitro anti-helminthic activity of *Martynia annua* Linn and *Permotrema reticulatum*. *Asian Journal of Biomaterial Research*; 1(2):72-74.
34. Kaur, P., Kataria, S.K., Singh, B., Arora, S. (2018). Pharmacognostic profile of *Trigonella corniculata* L. seeds and effect of its aqueous extract on growth inhibition of cancer cells. *Research J. Pharm. and Tech*; 2022-2029.
35. Mahto, B.K., Patel, R., Bapna, R., Shukla, A.K. (2022). Assessment of antioxidant, anticancer activity of standardized poly-herbal capsule formulation. *Neuro Quantology*; 20(9):4187-4203.
36. Razali, S., Firus, Khan, A., Khatib, A., Ahmed, Q., Abdul, Wahab., R., Zakaria, Z. (2021). An In-vitro anticancer activity evaluation of *Neolamarckia cadamba* (roxb.) bosser leaves' extract and its metabolite profile. *Front. Pharmacol*; 1-4.
37. Shahnawaz, M., Goswami, S., Shukla, A. K. (2019). Preliminary assessment of *Calotropis gigantea* leaves extract for in-vitro antidiabetic activity. *Advance Pharmaceutical Journal*; 4(5):128-132.
38. Tiwari, R., Shukla, A.K. (2020). Plant metabolites and their role in health benefits: A brief review. *Advance Pharmaceutical Journal*; 5(2):47-53.

#### CITATION OF THIS ARTICLE

Binay K M, Rajendra B, Ajay K S. Evaluation of *in-vitro* anticancer activity assessment on breast cancer cell line MCF-7. *Bull. Env. Pharmacol. Life Sci.*, Vol 12[6] May 2023: 92-96.